Multi-institutional Development and External Validation of a Nomogram Predicting Recurrence After Curative Liver Resection for Neuroendocrine Liver Metastasis

[1]  T. Pawlik,et al.  New Nodal Staging for Primary Pancreatic Neuroendocrine Tumors: A Multi-institutional and National Data Analysis. , 2019, Annals of surgery.

[2]  S. Pappas,et al.  Primary Tumor Site Affects Survival in Patients with Gastroenteropancreatic and Neuroendocrine Liver Metastases , 2019, International journal of endocrinology.

[3]  V. Nosé,et al.  Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances , 2019, Advances in anatomic pathology.

[4]  T. Pawlik,et al.  Early recurrence of well‐differentiated (G1) neuroendocrine liver metastasis after curative‐intent surgery: Risk factors and outcome , 2018, Journal of surgical oncology.

[5]  G. Rindi,et al.  The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia. , 2018, Endocrinology and metabolism clinics of North America.

[6]  T. Fahey,et al.  Predicting Survival and Response to Treatment in Gastroesophageal Neuroendocrine Tumors: An Analysis of the National Cancer Database , 2018, Annals of Surgical Oncology.

[7]  A. Ejaz,et al.  The impact of extrahepatic disease among patients undergoing liver‐directed therapy for neuroendocrine liver metastasis , 2017, Journal of surgical oncology.

[8]  M. Choti,et al.  Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases , 2017, Annals of surgery.

[9]  Minhu Chen,et al.  Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms , 2017, British Journal of Cancer.

[10]  T. Pawlik,et al.  Early Recurrence of Neuroendocrine Liver Metastasis After Curative Hepatectomy: Risk Factors, Prognosis, and Treatment , 2017, Journal of Gastrointestinal Surgery.

[11]  R. Lloyd,et al.  WHO classification of tumours of endocrine organs , 2017 .

[12]  G. Spolverato,et al.  Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: An international multi‐institutional analysis , 2017, Journal of surgical oncology.

[13]  G. Spolverato,et al.  Neuroendocrine liver metastasis: The chance to be cured after liver surgery , 2017, Journal of surgical oncology.

[14]  T. Pawlik,et al.  Parenchymal-Sparing Versus Anatomic Liver Resection for Colorectal Liver Metastases: a Systematic Review , 2017, Journal of Gastrointestinal Surgery.

[15]  M. Makuuchi,et al.  Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. , 2016, Journal of hepatology.

[16]  E. Krenning,et al.  ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site , 2016, Neuroendocrinology.

[17]  A. Bellizzi,et al.  Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy? , 2016, Surgery.

[18]  A. Ejaz,et al.  Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model. , 2015, Surgery.

[19]  R. Schilsky,et al.  Recommendations for management of patients with neuroendocrine liver metastases. , 2014, The Lancet. Oncology.

[20]  S. Imbeaud,et al.  A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. , 2013, Gastroenterology.

[21]  T. Pawlik,et al.  Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies. , 2013, Journal of the American College of Surgeons.

[22]  T. Chua,et al.  Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. , 2012, Surgical oncology.

[23]  A. Scarpa,et al.  Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. , 2012, European journal of cancer.

[24]  Domenico Coppola,et al.  The Pathologic Classification of Neuroendocrine Tumors: A Review of Nomenclature, Grading, and Staging Systems , 2010, Pancreas.

[25]  M. Choti,et al.  Surgical Management of Hepatic Neuroendocrine Tumor Metastasis: Results from an International Multi-Institutional Analysis , 2010, Annals of Surgical Oncology.

[26]  D. Le Guludec,et al.  Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience. , 2009, Endocrine-related cancer.

[27]  V. Pamecha,et al.  Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. , 2009, The Cochrane database of systematic reviews.

[28]  Shahrokh F. Shariat,et al.  Comparison of Nomograms With Other Methods for Predicting Outcomes in Prostate Cancer: A Critical Analysis of the Literature , 2008, Clinical Cancer Research.

[29]  A. Scarpa,et al.  Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  T. Fahey.  Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival , 2008 .

[31]  C. Bordi,et al.  Prognostic Factors in Gastrointestinal Endocrine Tumors , 2007, Endocrine pathology.

[32]  M. Milas,et al.  Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. , 2007, Surgery.

[33]  A. Scarpa,et al.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system , 2006, Virchows Archiv : an international journal of pathology.

[34]  D. Santini,et al.  Endocrine pancreatic tumors: factors correlated with survival. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  D. Nagorney,et al.  Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. , 2003, Journal of the American College of Surgeons.

[36]  T. Pawlik,et al.  Combined Resection and Radiofrequency Ablation for Advanced Hepatic Malignancies: Results in 172 Patients , 2003, Annals of Surgical Oncology.

[37]  P. Lavin,et al.  Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. , 1998, Annals of surgery.

[38]  O. Beahrs.  The American Joint Committee on Cancer. , 1984, Bulletin of the American College of Surgeons.